Calypso Biotech B.V. (Amsterdam, the Netherlands) closed the first tranche of a €20 million ($22.6 million) series A round Feb. 20, with enough funding to begin clinical studies of its lead candidate to treat eosinophilic esophagitis.
The round was led by Gilde Healthcare Partners and INKEF Capital, who joined Johnson & Johnson Innovation - JJDC Inc. and founding investor M Ventures, the investment arm of Merck KGaA (Xetra:MRK)...
BCIQ Target Profiles